Scott R Penzak

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers
    Scott R Penzak
    Department of Pharmacy Practice, Mercer University, Southern School of Pharmacy, Atlanta, Georgia, USA
    J Clin Psychopharmacol 22:366-70. 2002
  2. pmc Limitations of using a single postdose midazolam concentration to predict CYP3A-mediated drug interactions
    Scott R Penzak
    Clinical Pharmacokinetics Research Laboratory, National Institutes of Health, Clinical Center Pharmacy Department, Bldg 10, Room 1N 257, Bethesda, MD 20892, USA
    J Clin Pharmacol 48:671-80. 2008
  3. pmc Echinacea purpurea significantly induces cytochrome P450 3A activity but does not alter lopinavir-ritonavir exposure in healthy subjects
    Scott R Penzak
    Clinical Pharmacokinetics Research Laboratory, Pharmacy Department, National Institutes of Health, Bethesda, MD 20892, USA
    Pharmacotherapy 30:797-805. 2010
  4. ncbi request reprint Management of protease inhibitor-associated hyperlipidemia
    Scott R Penzak
    Clinical Pharmacokinetics Laboratory, Clinical Center Pharmacy Department, National Institutes of Health, Bethesda, Maryland 20892, USA
    Am J Cardiovasc Drugs 2:91-106. 2002
  5. ncbi request reprint Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers
    Scott R Penzak
    Warren G Magnuson Clinical Center, Pharmacy Department, National Institutes of Health, Bethesda, MD 20892, USA
    J Acquir Immune Defic Syndr 40:573-80. 2005
  6. ncbi request reprint Antiretroviral drug content in products from developing countries
    Scott R Penzak
    Department of Pharmacy, Warren G Magnuson Clinical Center, Bethesda, Maryland, USA
    Clin Infect Dis 38:1317-9. 2004
  7. pmc Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals
    Kristin H Busse
    Pharmacy Department, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, MD, USA
    J Acquir Immune Defic Syndr 48:561-6. 2008
  8. ncbi request reprint Lack of in vivo correlation between indinavir and saquinavir exposure and cytochrome P450 3A phenotype as assessed with oral midazolam as a phenotype probe
    Sarah M Robertson
    Department of Pharmacy, Clinical Research Center, National Institutes of Health, Bethesda, Maryland 20892, USA
    Pharmacotherapy 26:1051-9. 2006
  9. pmc Lack of sex-related differences in saquinavir pharmacokinetics in an HIV-seronegative cohort
    Sarah M Robertson
    Clinical Research Center, Department of Critical Care Medicine, National Institutes of Health, Bethesda, MD 20892, USA
    Br J Clin Pharmacol 61:379-88. 2006
  10. doi request reprint Lack of an Effect of Ritonavir Alone and Lopinavir-Ritonavir on the Pharmacokinetics of Fenofibric Acid in Healthy Volunteers
    Lori A Gordon
    Pharmacy Department, NIH Clinical Center, National Institutes of Health, Bethesda, Maryland
    Pharmacotherapy 36:49-56. 2016

Detail Information

Publications46

  1. ncbi request reprint Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers
    Scott R Penzak
    Department of Pharmacy Practice, Mercer University, Southern School of Pharmacy, Atlanta, Georgia, USA
    J Clin Psychopharmacol 22:366-70. 2002
    ..001) after ritonavir. Ritonavir significantly reduced the systemic exposure of olanzapine in volunteers. Patients receiving this combination may ultimately require higher olanzapine doses to achieve desired therapeutic effects...
  2. pmc Limitations of using a single postdose midazolam concentration to predict CYP3A-mediated drug interactions
    Scott R Penzak
    Clinical Pharmacokinetics Research Laboratory, National Institutes of Health, Clinical Center Pharmacy Department, Bldg 10, Room 1N 257, Bethesda, MD 20892, USA
    J Clin Pharmacol 48:671-80. 2008
    ....
  3. pmc Echinacea purpurea significantly induces cytochrome P450 3A activity but does not alter lopinavir-ritonavir exposure in healthy subjects
    Scott R Penzak
    Clinical Pharmacokinetics Research Laboratory, Pharmacy Department, National Institutes of Health, Bethesda, MD 20892, USA
    Pharmacotherapy 30:797-805. 2010
    ..To determine the influence of Echinacea purpurea on the pharmacokinetics of lopinavir-ritonavir and on cytochrome P450 (CYP) 3A and P-glycoprotein activity by using the probe substrates midazolam and fexofenadine, respectively...
  4. ncbi request reprint Management of protease inhibitor-associated hyperlipidemia
    Scott R Penzak
    Clinical Pharmacokinetics Laboratory, Clinical Center Pharmacy Department, National Institutes of Health, Bethesda, Maryland 20892, USA
    Am J Cardiovasc Drugs 2:91-106. 2002
    ....
  5. ncbi request reprint Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers
    Scott R Penzak
    Warren G Magnuson Clinical Center, Pharmacy Department, National Institutes of Health, Bethesda, MD 20892, USA
    J Acquir Immune Defic Syndr 40:573-80. 2005
    ..Ritonavir significantly increased the systemic exposure of prednisolone in healthy subjects. Results from this investigation suggest that corticosteroid exposure is likely elevated in HIV-infected patients receiving protease inhibitors...
  6. ncbi request reprint Antiretroviral drug content in products from developing countries
    Scott R Penzak
    Department of Pharmacy, Warren G Magnuson Clinical Center, Bethesda, Maryland, USA
    Clin Infect Dis 38:1317-9. 2004
    ..We analyzed 6 antiretroviral medications from 4 international sources for drug content. The active ingredient in tested drug products was within 15% of the labeled amount (range, -12% to +15%) for drugs that were properly stored...
  7. pmc Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals
    Kristin H Busse
    Pharmacy Department, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, MD, USA
    J Acquir Immune Defic Syndr 48:561-6. 2008
    ..In a study in healthy volunteers, ritonavir significantly increased prednisolone exposure...
  8. ncbi request reprint Lack of in vivo correlation between indinavir and saquinavir exposure and cytochrome P450 3A phenotype as assessed with oral midazolam as a phenotype probe
    Sarah M Robertson
    Department of Pharmacy, Clinical Research Center, National Institutes of Health, Bethesda, Maryland 20892, USA
    Pharmacotherapy 26:1051-9. 2006
    ..To investigate a potential correlation between exposure to oral midazolam, a commonly used cytochrome P450 (CYP) 3A probe, and saquinavir and indinavir exposure...
  9. pmc Lack of sex-related differences in saquinavir pharmacokinetics in an HIV-seronegative cohort
    Sarah M Robertson
    Clinical Research Center, Department of Critical Care Medicine, National Institutes of Health, Bethesda, MD 20892, USA
    Br J Clin Pharmacol 61:379-88. 2006
    ..To examine the influence of sex on steady-state saquinavir pharmacokinetics in HIV-seronegative volunteers administered saquinavir without a concomitant protease inhibitor...
  10. doi request reprint Lack of an Effect of Ritonavir Alone and Lopinavir-Ritonavir on the Pharmacokinetics of Fenofibric Acid in Healthy Volunteers
    Lori A Gordon
    Pharmacy Department, NIH Clinical Center, National Institutes of Health, Bethesda, Maryland
    Pharmacotherapy 36:49-56. 2016
    ....
  11. pmc Influence of Panax ginseng on cytochrome P450 (CYP)3A and P-glycoprotein (P-gp) activity in healthy participants
    Christine Y Malati
    Clinical Pharmacokinetics Research Laboratory, Pharmacy Department, Clinical Research Center, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Clin Pharmacol 52:932-9. 2012
    ..Patients taking P ginseng in combination with CYP3A substrates with narrow therapeutic ranges should be monitored closely for adequate therapeutic response to the substrate medication...
  12. pmc Gemfibrozil concentrations are significantly decreased in the presence of lopinavir-ritonavir
    Kristin H Busse
    Clinical Pharmacokinetics Research Laboratory, Pharmacy Department, National Institutes of Health Clinical Center, Bethesda, MD, USA
    J Acquir Immune Defic Syndr 52:235-9. 2009
    ..The objective of this study was to determine the influence of a 2-week course of lopinavir-ritonavir on the pharmacokinetics of the triglyceride-lowering agent, gemfibrozil...
  13. pmc Pharmacokinetics of intravenous voriconazole in obese patients: implications of CYP2C19 homozygous poor metabolizer genotype
    Brad Moriyama
    Pharmacy Department, National Institutes of Health Clinical Center, Bethesda, MD 20892, USA
    Pharmacotherapy 33:e19-22. 2013
    ..If an obese patient dosed on total body weight is also a CYP2C19 poor metabolizer, serum voriconazole concentrations will be further elevated, potentially leading to drug-induced toxicity...
  14. doi request reprint Lack of a pharmacokinetic drug-drug interaction with venlafaxine extended-release/indinavir and desvenlafaxine extended-release/indinavir
    Michael W Jann
    Mercer University College of Pharmacy and Health Sciences, 3001 Mercer University Dr, Atlanta, GA 30341, USA
    Eur J Clin Pharmacol 68:715-21. 2012
    ..To assess the effects of venlafaxine extended-release (XR) capsules and desvenlafaxine extended-release (XR) tablets upon indinavir pharmacokinetic properties when co-administrated to healthy volunteers...
  15. ncbi request reprint Ritonavir decreases the nonrenal clearance of digoxin in healthy volunteers with known MDR1 genotypes
    Scott R Penzak
    Warren G Magnuson Clinical Center, Pharmacy Department, National Institutes of Health, Bethesda, Maryland 20892, USA
    Ther Drug Monit 26:322-30. 2004
    ..The most likely mechanism for this interaction is ritonavir-associated inhibition of P-gp. Thus, ritonavir can alter the pharmacokinetics of coadministered medications that are P-gp substrates...
  16. ncbi request reprint Drug interactions in the management of HIV infection: an update
    Sarah M Robertson
    US Food and Drug Administration, Office of Clinical Pharmacology, Center for Drug Evaluation and Research, Silver Spring, Maryland, USA
    Expert Opin Pharmacother 8:2947-63. 2007
    ..This review provides an update to a previous review article published in 2005, and is intended to improve the reader's knowledge of drug interactions in the management of HIV infection...
  17. ncbi request reprint Influence of grapefruit juice on the systemic availability of itraconazole oral solution in healthy adult volunteers
    Paul O Gubbins
    Department of Pharmacy Practice, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock 72205 7122, USA
    Pharmacotherapy 24:460-7. 2004
    ....
  18. ncbi request reprint Risk-benefit of HMG-CoA reductase inhibitors in the treatment of HIV protease inhibitor-related hyperlipidaemia
    Susan K Chuck
    Department of Pharmacy and Drug Information, Grady Health System I D Program, 341 Ponce de Leon Avenue NE, Atlanta, GA 30308, USA
    Expert Opin Drug Saf 1:5-17. 2002
    ..Pravastatin has an acceptable risk-benefit ratio in PIH, while theoretical toxicity concerns exist with atorvastatin...
  19. pmc Adverse interactions between antifungal azoles and vincristine: review and analysis of cases
    Brad Moriyama
    NIH Clinical Center Pharmacy Department, Bethesda, MD, USA
    Mycoses 55:290-7. 2012
    ..Recovery from these ADIs occurred in 80.6% of patients. We recommend using alternative antifungal agents if possible in patients receiving vincristine to avoid this serious and potentially life-threatening drug interaction...
  20. ncbi request reprint A potentially significant interaction between efavirenz and phenytoin: a case report and review of the literature
    Sarah M Robertson
    Clinical Pharmacokinetics Research Laboratory, Clinical Center Pharmacy Department, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Clin Infect Dis 41:e15-8. 2005
    ..Therapeutic drug monitoring was used in this case to ensure adequate efavirenz exposure...
  21. ncbi request reprint Drug interactions in the management of HIV infection
    Sarah M Robertson
    National Institutes of Health, Clinical Pharmacokinetics Research Laboratory, Clinical Center Pharmacy Department, Bethesda, Maryland 20892, USA
    Expert Opin Pharmacother 6:233-53. 2005
    ..The mechanisms and significance of interactions involving antiretrovirals, drugs used for opportunistic infections, and other medications commonly used in HIV patients will be reviewed...
  22. pmc Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole
    Brad Moriyama
    NIH Clinical Center, Pharmacy Department, Bethesda, MD
    Curr Fungal Infect Rep 9:74-87. 2015
    ..Additional studies are needed before implementation of CYP2C19 genotyping for voriconazole dosing into routine clinical care...
  23. pmc Emerging drugs and vaccines for candidemia
    Brad Moriyama
    Pharmacy Department, NIH Clinical Center, Bethesda, MD, USA
    Mycoses 57:718-33. 2014
    ..Still, there remains a critical need for new antifungal agents to treat and prevent invasive candidiasis and other life-threatening mycoses. ..
  24. pmc Impaired maraviroc and raltegravir clearance in a human immunodeficiency virus-infected patient with end-stage liver disease and renal impairment: a management dilemma
    Alice K Pau
    Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Pharmacotherapy 32:e1-6. 2012
    ..Until more data are available, therapeutic drug monitoring remains the only evidence-based approach to optimize dosage selection of these drugs in this patient population...
  25. doi request reprint The postantifungal and paradoxical effects of echinocandins against Candida spp
    Brad Moriyama
    NIH Clinical Center, Pharmacy Department, Bethesda, MD, USA
    Future Microbiol 7:565-9. 2012
    ..The report by Shields et al. illustrates that short exposures to an echinocandin may lead to prolonged postantifungal effects and furthers our understanding of the paradoxical effect in C. albicans...
  26. ncbi request reprint Effect of Seville orange juice and grapefruit juice on indinavir pharmacokinetics
    Scott R Penzak
    Department of Pharmacy Practice, Mercer University, Southern School of Pharmacy, Atlanta, Georgia, USA
    J Clin Pharmacol 42:1165-70. 2002
    ..Modulation of intestinal CYP3A4 by grapefruit juice and Seville orange juice did not alter the systemic availability of indinavir. The contribution of presystemic metabolism to indinavir interpatient variability appears to be small...
  27. pmc The pharmacodynamic equivalence of levothyroxine and liothyronine: a randomized, double blind, cross-over study in thyroidectomized patients
    Francesco S Celi
    Clinical Endocrinology Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Building 10, CRC, RM 6 3940, 10 Center Drive, MSC 1613, Bethesda, MD 20892 1613, USA
    Clin Endocrinol (Oxf) 72:709-15. 2010
    ..Presently, only limited data are available on the L-T3 for L-T4 therapeutic substitution. Objective To characterize the pharmcodynamic equivalence of L-T3 and L-T4...
  28. pmc Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition
    Raphaela Goldbach-Mansky
    National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    N Engl J Med 355:581-92. 2006
    ..Many patients have mutations in the cold-induced autoinflammatory syndrome 1 (CIAS1) gene, encoding cryopyrin, a protein that regulates inflammation...
  29. ncbi request reprint Darunavir: a second-generation protease inhibitor
    Kristin H S Busse
    Pharmacy Department, Clinical Center, National Institutes of Health, Bethesda, MD 20896 1196, USA
    Am J Health Syst Pharm 64:1593-602. 2007
    ..The pharmacology, pharmacokinetics, drug interactions, clinical efficacy, adverse events, dosage and administration, and place in therapy of darunavir are reviewed...
  30. pmc Markers of endothelial dysfunction, coagulation and tissue fibrosis independently predict venous thromboembolism in HIV
    Laura W Musselwhite
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, USA
    AIDS 25:787-95. 2011
    ..We investigated the relationship between venous thrombosis and HIV-related characteristics, traditional risk factors of hypercoagulability, and pre-event levels of biomarkers...
  31. doi request reprint Clinical Pharmacogenetics Implementation Consortium (CPIC®) Guideline for CYP2C19 and Voriconazole Therapy
    Brad Moriyama
    NIH Clinical Center Pharmacy Department, Bethesda, MD, USA
    Clin Pharmacol Ther . 2016
    ..org/guidelines/ and www.pharmgkb.org). This article is protected by copyright. All rights reserved...
  32. doi request reprint Influence of Panax ginseng on the steady state pharmacokinetic profile of lopinavir-ritonavir in healthy volunteers
    Monica M Calderon
    Clinical Research Center, Clinical Center Pharmacy Department, National Institutes of Health, Bethesda, Maryland
    Pharmacotherapy 34:1151-8. 2014
    ..Therefore, the purpose of this study was to determine the influence of P. ginseng on the pharmacokinetics of the HIV protease inhibitor combination lopinavir-ritonavir (LPV-r) in healthy volunteers...
  33. doi request reprint Pharmacology and antifungal properties of anidulafungin, a new echinocandin
    Kristina E Estes
    Clinical Center Pharmacy Department, National Institutes of Health, Bethesda, Maryland 20892, USA
    Pharmacotherapy 29:17-30. 2009
    ..The safety, tolerability, and potent fungicidal activity of anidulafungin against Candida species make it a reasonable alternative in the treatment of patients with serious candidal infections...
  34. pmc Part 2 - Coronary angiography with gadofosveset trisodium: a prospective intra-subject comparison for dose optimization for 100 % efficiency imaging
    Mark A Ahlman
    National Institutes of Health, Radiology and Imaging Sciences, Clinical Center, 10 Center Drive, Building 10, Rm B1N264B 7, Bethesda, MD, 20892, USA
    BMC Cardiovasc Disord 16:58. 2016
    ..The goal of this study was to evaluate if there is a qualitative or quantitative improvement in the coronary arteries with variation in contrast dose...
  35. pmc Integrating pharmacogenetic information and clinical decision support into the electronic health record
    Barry R Goldspiel
    Pharmacy Department, National Institutes of Health Clinical Center, Bethesda, Maryland, USA
    J Am Med Inform Assoc 21:522-8. 2014
    ..Prescribers have adapted to using the CDS and have ordered PG testing as a direct result of the implementation. ..
  36. doi request reprint Pharmacological enhancement of protease inhibitors with ritonavir: an update
    Kristin H Busse
    Clinical Pharmacokinetics Research Fellow, National Institutes of Health, Clinical Center Pharmacy Department, 9000 Rockville Pike, Building 10, Room 1N 257, Bethesda, MD 20896 1196, USA
    Expert Rev Clin Pharmacol 1:533-45. 2008
    ..This article reviews the pharmacological use of ritonavir for pharmacokinetic enhancement (or boosting) and updates the clinical use of boosted protease inhibitors. ..
  37. pmc Pharmacokinetics of anidulafungin in pleural fluid during the treatment of a patient with Candida empyema
    Brad Moriyama
    NIH Clinical Center, Pharmacy Department, National Heart Lung and Blood Instititute, Bethesda, MD, USA
    Antimicrob Agents Chemother 55:2478-80. 2011
    ..125 (12.5%), with pleural fluid concentrations ranging between 0.67 and 0.88 μg/ml...
  38. ncbi request reprint Safety, tolerability, and pharmacokinetics of high-dose idebenone in patients with Friedreich ataxia
    Nicholas A Di Prospero
    Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892 3705, USA
    Arch Neurol 64:803-8. 2007
    ..Some studies suggest that higher doses of idebenone may be more effective, but pharmacology and toxicology at higher doses have not been investigated in human beings...
  39. ncbi request reprint Tenofovir: a nucleotide analogue reverse-transcriptase inhibitor for treatment of HIV infection
    Robert Dechristoforo
    Pharmacy Department, National Institutes of Health, Building 10, Room 1N 257 MSC 1196, 10 Center Drive, Bethesda, MD 20892 1196, USA
    Am J Health Syst Pharm 61:86-98; quiz 99-100. 2004
  40. doi request reprint Antiviral therapy in patients with hematologic malignancies, transplantation, and aplastic anemia
    Timothy Jancel
    Clinical Center Pharmacy Department, National Institutes of Health, Bethesda, MD 20892 1196, USA
    Semin Hematol 46:230-47. 2009
    ..Antiviral agents used for the treatment of HIV and viral hepatitis will not be addressed in this review...
  41. doi request reprint Examining sex-related differences in enteric itraconazole metabolism in healthy adults using grapefruit juice
    Paul O Gubbins
    College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR 72205 7122, USA
    Eur J Clin Pharmacol 64:293-301. 2008
    ..To explore whether sex-related differences in intestinal itraconazole metabolism exist in healthy adults using grapefruit juice (GFJ) as a selective enteric cytochrome P450 3A4 (CYP3A4) inhibitor...
  42. ncbi request reprint Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects
    Sarah M Robertson
    Office of Clinical Pharmacology, Center for Drug Evaluation and Research, US Food and Drug Administration, New Hampshire Ave, Silver Spring, MD 20901, USA
    Curr Med Res Opin 24:591-9. 2008
    ..Secondary objectives were to compare ritonavir exposure pre- and post-GBE, and assess the effect of GBE on single doses of probe drugs midazolam and fexofenadine...
  43. ncbi request reprint Does metronidazole interact with CYP3A substrates by inhibiting their metabolism through this metabolic pathway? Or should other mechanisms be considered?
    Rhonda Roedler
    Peter Lougheed Centre, Calgary, Alberta, Canada
    Ann Pharmacother 41:653-8. 2007
    ..To explore whether CYP3A inhibition by metronidazole is the primary mechanism by which metronidazole interacts with coadministered CYP3A substrates...
  44. ncbi request reprint Analysis of generic nevirapine products in developing countries
    Scott R Penzak
    JAMA 289:2648-9. 2003
  45. ncbi request reprint Correlation of cytochrome P450 (CYP) 1A2 activity using caffeine phenotyping and olanzapine disposition in healthy volunteers
    Kara Lee Shirley
    Albany College of Pharmacy, Albany, NY, USA
    Neuropsychopharmacology 28:961-6. 2003
    ..Interpatient variability in CYP1A2 activity may explain the wide interpatient variability in olanzapine disposition. Compounds that modulate CYP1A2 activity may be expected to alter olanzapine pharmacokinetics accordingly...
  46. pmc Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients
    Paul O Gubbins
    College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, 72205, USA
    Antimicrob Agents Chemother 50:1993-9. 2006
    ..1483). Moreover, this reduction could be overcome by increasing the total dose and dosing frequency. Posaconazole was safe and well tolerated...